4th World Conference on Cancer Research and Biomarkers

Jul 27-28, 2022


San Francisco, United States of America

LexisConferences invites all the participants from all over the world to attend “4th World Conference on Cancer Research and Biomarkers” during July 27-28, 2022 in San Francisco, USA.

This conference will offer you uncommon prospects to arrange with Academic and Clinical oncology Specialists, Clinical oncology Researchers, Medical Research Departments, Faculty of Health Sciences, C-level authority, Faculty of Healthcare, Deans, Professors and PhD Students from Medical Universities. It is an overall stage to look at and get some answers concerning Fostering and Latest Innovations in Cancer Diagnosis. Biomarkers on the other hand , give a dynamic and incredible way to deal with understanding the range of ailments with evident applications in systematic the study of disease transmission, biomarkers and clinical research in sickness avoidance, conclusion and illness the executives. Biomarkers have the extra potential to recognize people powerless to specific sicknesses. In the on-going years, the data about malignancy biomarkers has expanded to a great extent giving an immense potential to enhancing the administration of disease patients by enhancing the exactness of recognition and viability of treatment. This meeting additionally incorporates symposia and workshop occasions and especially urge to spread the information of steady disclosures and logical research refreshes in nowadays.

Details of World Cancer 2022 in USA:

Conference Name Place Date
World Cancer 2022

San Francisco, USA

July 27-28, 2022

Market Analysis:

The global cancer therapeutics market size was estimates at $98,900 million in 2018 and is estimated to succeed in at $180,193 million by 2026, enrolling a CAGR of seven .7% from 2019 to 2026. Cancer therapeutics involves the utilize and processing of chemotherapy and oncology drugs to treat cancer.

Increase in cancer prevalence, surge together between pharmaceutical companies, and rise in cancer research are the key factors that augment the expansion of the cancer therapeutics market. Furthermore, growth in geriatric population is predicted to spice up the market growth.

However, high cost related to oncology drug development alongside adverse effects related to cancer therapeutics are several  factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is predicted to supply new opportunities for the market players in future.

The cancer therapeutics market is segmented supported application, top selling drugs, and region. supported application, the market is split into blood cancer, carcinoma, colorectal cancer, prostatic adenocarcinoma , carcinoma , cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, et al. . By top selling drugs, it's categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, et al. . Region wise, it's analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The global cancer therapeutics market trends are examined through the application vertical in the report. The lung cancer segment controlled the cancer therapeutics market, owing to the surge in frequency of lung cancer and favorable government regulations toward lung cancer therapeutics.

 The global cancer therapeutics market growth is also studied through the top selling drugs vertical in the report. The Revlimid segment occupied the largest share in the cancer therapeutics market in 2018, owing to the face that it received a breakthrough therapy designation. Revlimid (lenalidomide) belongs to the class of immunomodulatory drugs. It is an oral cancer drug indicated for multiple myeloma treatment. Revlimid functions against cancer cells partly by impacting the immune system. In October 2016, the combination therapy results of Revlimid and daratumumab (Johnson and Johnson) reported a surge in progression-free survival rate for patients suffering from refractory or relapsed multiple myeloma (or MM). This combination treatment was granted a breakthrough therapy designation by the FDA in July 2016. 


  • This report entails a detailed quantitative cancer therapeutics market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
  • Market size and estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
  • An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.



  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Glioblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others


  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Temodar
  • Others


  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
    • Latin America
    • Middle-East
    • Africa

Market Analysis on Biomarkers:

The global biomarkers market is estimated to succeed in USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Growth in the global biomarkers manufacturing is mainly driven by factors such as increasing diagnostic tenders of biomarkers, increasing R&D funding for pharma and biotech companies, collective number of CROs and low cost of clinical trials in emerging countries, the high prevalence of cancer, and new initiatives for research. On the opposite hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues associated with sample collection and storage are the main factors restraining the growth of this market.

The global cancer biomarkers market is accounted for USD 10.31 billion in 2016 and is predictable to grow at a CAGR of 12.2% to USD 20.48 billion by 2022 during the projection period. Due to the growing prevalence of cancer worldwide, the utilization of cancer biomarkers has increased significantly in recent years, providing opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment. Cancer biomarkers are present in tumor tissues or sera and encompass a good sort of molecules, including DNA, mRNA, transcription factors, cell surface receptors, and secreted proteins. These biomarkers are often used for the prognosis and predicting the natural course of a tumor. They can also help doctors decide which patients are likely to reply to a given drug (prediction) and at what dosage it'd be best (pharmacodynamics).


Program Overview